NCT02387814View on ClinicalTrials.gov

A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Hepatic Insufficiency
Interventions
DRUG

Abemaciclib

Administered Orally

Trial Locations (5)

32809

Orlando Clinical Research Center (OCRC), Orlando

33014

Clinical Pharmacology of Miami (CPMI), Miami

46202

Indiana University - Digestive and Liver Diseases, Indianapolis

55404

DaVita Clinical Research, Minneapolis

80228

DaVita Clinical Research, Lakewood

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02387814 - A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment | Biotech Hunter | Biotech Hunter